Zilbrysq Injection, Solution
Product Images NDC 50474-992

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Zilbrysq (NDC 50474-992). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zilbrysq 01)

Chemical structure diagram of the active ingredient zilucoplan showing a detailed peptide chain with labeled amino acid residues and associated chemical groups.*

FDA Label Image

Figure 1 (Zilbrysq 02)

Two line graphs comparing placebo and ZILBRYSQ 0.3 mg/kg groups over 12 weeks. Graph A shows LS mean changes in MG-ADL score, and Graph B shows LS mean changes in QMG score, with ZILBRYSQ resulting in greater reductions in both scores over time. Error bars indicate variability, with p-values less than 0.001 and 0.0001, respectively.*

FDA Label Image

Figure A (Zilbrysq 03)

An instructional diagram of the ZILBRYSQ 40 mg/mL subcutaneous injection syringe, showing labeled parts including plunger head and rod, finger grip, syringe body, syringe label with expiration date and product name, needle guard activation clips, and needle cap.*

FDA Label Image

Figure A (Zilbrysq 04)

An instructional diagram showing a cross-sectional view of an automatic needle guard mechanism in a syringe for ZILBRYSQ injection. The image illustrates the needle guard locked and how it automatically pulls back (retracts) the needle after injection for safety.*

FDA Label Image

Figure B.1 (Zilbrysq 05)

An illustration showing a hand withdrawing a dose from a vial using a syringe. The vial is held in a container with dividers, suggesting organization for multiple vials, likely related to injectable medication preparation.*

FDA Label Image

Figure B.2 (Zilbrysq 06)

An instructional line drawing showing a hand holding a prefilled syringe with a needle attached, illustrating the proper grip technique for administering a subcutaneous injection.*

FDA Label Image

Figure C (Zilbrysq 07)

Illustration of a prefilled syringe for ZILBRYSQ (zilucoplan) injection, solution, showing the syringe label with expiration date and product name, the medicine contained inside, and the needle cap.*

FDA Label Image

Figure D (Zilbrysq 08)

An instructional illustration showing components and supplies for subcutaneous injection. The image includes a syringe with plunger, an alcohol prep pad, a cotton ball, a bandage strip, and a sharps disposal container.*

FDA Label Image

Figure E.1 (Zilbrysq 09)

An instructional illustration showing a human figure with highlighted areas commonly used for subcutaneous injection of ZILBRYSQ (zilucoplan) injection, solution. The abdomen around the navel and the front of the thighs are shaded as recommended injection sites.*

FDA Label Image

Figure E.2 (Zilbrysq 10)

An anatomical illustration showing the back view of a human torso with shaded areas on both upper arms near the shoulder, indicating injection sites for subcutaneous administration.*

FDA Label Image

Figure F (Zilbrysq 11)

An instructional illustration showing a hand cleaning a circular area of skin with a cloth or pad, indicating preparation of the injection site for subcutaneous administration.*

FDA Label Image

Figure G (Zilbrysq 12)

An instructional illustration showing a hand holding a prefilled syringe with a safety guard, and the other hand removing a small cap from the syringe tip, indicated by a red arrow. The image demonstrates a step in preparing the ZILBRYSQ 40 mg/mL subcutaneous injection for use.*

FDA Label Image

Figure H (Zilbrysq 13)

An instructional diagram showing a hand positioned on an abdomen area, likely demonstrating where to administer a subcutaneous injection. The illustration is simple with black line art on a white background, focusing on hand placement.*

FDA Label Image

Figure I (Zilbrysq 14)

An instructional illustration showing how to administer a subcutaneous injection using a syringe. The diagram emphasizes holding the needle at a 45 to 90-degree angle relative to the skin surface during injection.*

FDA Label Image

Figure J (Zilbrysq 15)

An instructional illustration showing a person holding a syringe with one hand while using the other hand to stretch the skin on the opposite arm, indicating preparation steps for a subcutaneous injection.*

FDA Label Image

Figure K (Zilbrysq 16)

An instructional illustration showing a hand holding a syringe or injection device with a red arrow indicating pressing down on the top of the device, likely demonstrating how to administer the injection.*

FDA Label Image

Figure L (Zilbrysq 17)

An instructional illustration showing a hand administering a subcutaneous injection using a prefilled syringe. The syringe is positioned with the needle inserted into the skin of the opposite forearm, demonstrating the injection technique typically used for subcutaneous solutions.*

FDA Label Image

Figure M (Zilbrysq 18)

An instructional diagram showing a vial with an inverted septum and a syringe positioned above it. A red arrow points downward from the syringe to the vial septum, indicating the action of inserting the syringe needle into the vial for medication withdrawal.*

FDA Label Image

Figure N (Zilbrysq 19)

An instructional illustration showing a hand pressing down on a circular area marked by an orange arrow, likely indicating an injection or application site on the skin.*

FDA Label Image

Figure O (Zilbrysq 20)

An illustration showing a hand applying a rectangular adhesive bandage with a central pad onto a flat surface, likely skin. The bandage has a grid of small holes visible on each side of the pad.*

FDA Label Image

Principal Display Panel (16.6 mg/0.416 mL Syringe Carton Box)

Packaging label for ZILBRYSQ (zilucoplan) injection, 16.6 mg/0.416 mL, a subcutaneous injection solution by UCB, Inc. The label set includes the outer carton design featuring a maroon background with white text and syringe illustration, along with fold lines and security features for a 28-single-dose prefilled syringe pack. The label displays the product name, strength, dosage form, route, and manufacturer details clearly.*

FDA Label Image

Principal Display Panel (23 mg/0.574 mL Syringe Carton Box)

Packaging label for ZILBRYSQ (zilucoplan) injection, 23 mg per 0.574 mL, intended for subcutaneous use only. The label shows a predominantly orange and white design featuring the brand and generic names, dosage strength, and an illustration of a prefilled syringe. The labeler is UCB, Inc., and the package contains 28 single-dose prefilled syringes.*

FDA Label Image

Principal Display Panel (32.4 mg/0.81 mL Syringe Carton Box)

Packaging label for ZILBRYSQ (zilucoplan) injection, 32.4 mg/0.81 mL, a subcutaneous injection. The label features the brand name and generic name prominently, dosage strength, and volume. The label includes instructions for use, storage conditions, barcode, and a syringe illustration. The packaging is primarily blue with white and yellow accents and is labeled for human prescription drug use by UCB, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.